雅虎香港 搜尋

登入

搜尋結果

  1. 6.170
    加入追蹤清單
    +0.180 (+3.01%)
    收市時間: 2024年5月10日, 週五 下午 4:08 HKT · (HKD)。延遲價格。市場已收市。
    全螢幕顯示
    • 前收市價
      5.990
      開市
      6.010
      買盤
      6.110
      賣出價
      6.170
    • 今日波幅
      5.980 - 6.260
      52週波幅
      3.730 - 12.000
      成交量
      1.73M
      平均成交量
      1.2M
    • 市值
      3.55B
      Beta值 (5年，每月)
      0.41
      市盈率 (最近12個月)
      不適用
      每股盈利 (最近12個月)
      -1.450
    • 業績公佈日
      2024-03-26
      遠期股息及收益率
      不適用 & 不適用
      除息日
      不適用
      1年預測目標價
      11.71

    查看更多2171.HK

    相關股票

    查看全部

  2. www.carsgen.com › en › newsNews | CARsgen

    2023年12月4日 · Dec 04, 2023. SHANGHAI, China, December 4, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that the U.S. Food and Drug Administration (FDA) has granted Investigational New Drug (IND ...

  3. www.carsgen.com › en › newsNews | CARsgen

    2024年3月27日 · Mar 27, 2024. SHANGHAI, China, March 26, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Annual Results. Business Highlights.

  4. www.carsgen.com › en › newsNewsroom | CARsgen

    2024年4月29日 · SHANGHAI, China, April 29, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that responses regarding the status of the Corrective and Preventive Actions (CAPAs) plan have been submitted to ...

  5. www.carsgen.com › en › newsNews | CARsgen

    2024年4月12日 · Apr 12, 2024. SHANGHAI, China, April 12, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that an abstract of satricabtagene autoleucel (“satri-cel”, CT041) (an autologous CAR T-cell ...

  6. www.carsgen.com › en › newsNews | CARsgen

    2023年8月22日 · SHANGHAI, August 22, 2023, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announced its 2023 Interim Results.

  7. www.carsgen.com › en › about-usCompany Overview | CARsgen

    CARsgen was listed on Hong Kong Exchanges and Clearing Limited (HKEX) (Stock Code: 2171.HK) Zevor-cel initiated phase 2 clinical trial in the U.S./Canada CT041 was granted Orphan Drug and PRIority Medicine (PRIME) by the European Medicines Agency

  8. www.carsgen.com › en › newsNews | CARsgen

    2024年3月1日 · SHANGHAI, China, March 1, 2024, CARsgen Therapeutics Holdings Limited (Stock Code: 2171.HK), a company focused on innovative CAR T-cell therapies for the treatment of hematologic malignancies and solid tumors, announces that today the National Medical Products Administration (“NMPA”) of China has approved the New Drug Application (“NDA”) for zev...